Tecentriq and Avastin revenue trends
In 1Q17, 2Q17, and 3Q17, Roche’s (RHHBY) Avastin generated revenues of 1.7 billion Swiss francs, 1.7 billion Swiss francs, and 1.6 billion Swiss francs, respectively. In 1Q17, 2Q17, and 3Q17, Tecentriq generated revenues of 115 million Swiss francs, 121 million Swiss francs, and 128 million Swiss francs, respectively.
IMmotion 151 trial
In December 2018, Roche announced results from the phase three IMmotion 151 trial. In the IMmotion 151 trial, Tecentriq and Avastin combination therapy met the co-primary endpoint of progression-free survival compared to sunitinib.
Roche conducted the phase three IMmotion 151 trial to evaluate the safety and efficacy of Tecentriq and Avastin combination therapy compared to sunitinib for the treatment of individuals with locally advanced or metastatic renal cell carcinoma who have not previously received systemic therapy.
In the IMmotion 151 trial, Tecentriq and Avastin demonstrated a statistically significant and clinically meaningful decrease in the risk of disease worsening or death (progression-free survival) in individuals with advanced or metastatic renal cell carcinoma whose tumors expressed PD-L1 (programmed death-ligand 1) protein compared to sunitinib as a first-line treatment.
The results of the clinical trial will be discussed with health authorities including the European Medicines Agency and the US Food and Drug Administration (or FDA).
About Tecentriq and Avastin
Tecentriq is indicated for the treatment of individuals with locally advanced or metastatic urothelial carcinoma who are not candidates for cisplatin-containing chemotherapy or showed disease progression during or after any platinum-containing chemotherapy. Tecentriq is also indicated for the treatment of individuals with metastatic non-small cell lung cancer who showed disease progression during or after platinum-containing chemotherapy. Avastin is indicated for metastatic colorectal cancer.
Tecentriq’s peers include Pfizer’s (PFE) Bavencio, Bristol-Myers Squibb’s (BMY) Opdivo, and Merck’s (MRK) Keytruda. The revenue growth of Roche’s Avastin and Tecentriq could boost the Vanguard FTSE All-World ex-US ETF (VEU). Roche makes up about ~0.69% of VEU’s total portfolio holdings.